Truist Securities Maintains Buy on Corcept Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Corcept Therapeutics (NASDAQ:CORT) with a $65 price target.
June 17, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Joon Lee has reaffirmed a Buy rating on Corcept Therapeutics with a $65 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $65 price target by Truist Securities suggests strong confidence in Corcept Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100